Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience’s Technology
Lexaria Bioscience (NASDAQ:LEXX) provides a strategic update on GLP-1 industry developments, highlighting its DehydraTECH technology's potential in enhancing oral drug delivery. Recent industry news includes Pfizer's discontinuation of danuglipron development due to liver injury concerns, while Eli Lilly reported positive phase 3 results for orfoglipron, leading to a $100 billion market valuation increase.
The company emphasizes that DehydraTECH has demonstrated enhanced delivery performance with existing oral GLP-1 drugs and shown potential in reducing common side effects that lead to high discontinuation rates (47-64% within 1-2 years). Lexaria is executing its strategy through collaborations, evidenced by a material transfer agreement with PharmaCO announced in September 2024.
The GLP-1 drug sector is expected to generate over $100 billion in annual revenue, with applications expanding across multiple healthcare sectors including cardiovascular disease, chronic kidney disease, obesity, and diabetes.
Lexaria Bioscience (NASDAQ:LEXX) fornisce un aggiornamento strategico sugli sviluppi nel settore GLP-1, evidenziando il potenziale della sua tecnologia DehydraTECH nel migliorare la somministrazione orale dei farmaci. Le ultime notizie del settore includono l'interruzione dello sviluppo di danuglipron da parte di Pfizer a causa di problemi epatici, mentre Eli Lilly ha riportato risultati positivi nella fase 3 per orfoglipron, portando a un aumento della valutazione di mercato di 100 miliardi di dollari.
L'azienda sottolinea che DehydraTECH ha dimostrato di migliorare la performance di somministrazione con i farmaci orali GLP-1 esistenti e ha mostrato potenzialità nel ridurre gli effetti collaterali comuni che causano alti tassi di interruzione (47-64% entro 1-2 anni). Lexaria sta attuando la sua strategia attraverso collaborazioni, come dimostra un accordo di trasferimento materiali con PharmaCO annunciato a settembre 2024.
Il settore dei farmaci GLP-1 dovrebbe generare oltre 100 miliardi di dollari di ricavi annui, con applicazioni in diversi ambiti sanitari tra cui malattie cardiovascolari, insufficienza renale cronica, obesità e diabete.
Lexaria Bioscience (NASDAQ:LEXX) ofrece una actualización estratégica sobre los avances en la industria GLP-1, destacando el potencial de su tecnología DehydraTECH para mejorar la administración oral de medicamentos. Las noticias recientes del sector incluyen la suspensión del desarrollo de danuglipron por parte de Pfizer debido a preocupaciones sobre lesiones hepáticas, mientras que Eli Lilly reportó resultados positivos en la fase 3 de orfoglipron, lo que llevó a un aumento en la valoración de mercado de 100 mil millones de dólares.
La compañía enfatiza que DehydraTECH ha demostrado un mejor desempeño en la entrega de medicamentos orales GLP-1 existentes y ha mostrado potencial para reducir los efectos secundarios comunes que provocan altas tasas de abandono (47-64% en 1-2 años). Lexaria está ejecutando su estrategia mediante colaboraciones, evidenciado por un acuerdo de transferencia de materiales con PharmaCO anunciado en septiembre de 2024.
Se espera que el sector de medicamentos GLP-1 genere más de 100 mil millones de dólares en ingresos anuales, con aplicaciones que se extienden a múltiples áreas de la salud, incluyendo enfermedades cardiovasculares, enfermedad renal crónica, obesidad y diabetes.
Lexaria Bioscience (NASDAQ:LEXX)는 GLP-1 산업 동향에 대한 전략적 업데이트를 제공하며, 경구 약물 전달을 향상시키는 DehydraTECH 기술의 잠재력을 강조합니다. 최근 업계 소식으로는 Pfizer가 간 손상 우려로 인해 danuglipron 개발을 중단했으며, Eli Lilly는 orfoglipron의 3상 시험에서 긍정적인 결과를 보고해 시장 가치가 1,000억 달러 증가했습니다.
회사는 DehydraTECH가 기존 경구 GLP-1 약물의 전달 성능을 향상시키고, 1-2년 내 47-64%에 이르는 높은 중단율을 유발하는 일반적인 부작용을 줄일 잠재력을 보였다고 강조합니다. Lexaria는 2024년 9월 PharmaCO와의 물질 이전 계약을 통해 협력 전략을 실행하고 있습니다.
GLP-1 약물 분야는 연간 1,000억 달러 이상의 수익을 창출할 것으로 예상되며, 심혈관 질환, 만성 신장 질환, 비만, 당뇨병 등 다양한 의료 분야에 적용 범위가 확대되고 있습니다.
Lexaria Bioscience (NASDAQ:LEXX) publie une mise à jour stratégique sur les développements de l'industrie GLP-1, mettant en avant le potentiel de sa technologie DehydraTECH pour améliorer la délivrance orale des médicaments. Les dernières nouvelles du secteur incluent l'arrêt par Pfizer du développement de danuglipron en raison de préoccupations liées à des lésions hépatiques, tandis qu'Eli Lilly a rapporté des résultats positifs en phase 3 pour l'orfoglipron, entraînant une augmentation de 100 milliards de dollars de la valorisation du marché.
L'entreprise souligne que DehydraTECH a démontré une meilleure performance de délivrance avec les médicaments oraux GLP-1 existants et a montré un potentiel pour réduire les effets secondaires courants responsables de taux élevés d'arrêt (47-64 % en 1 à 2 ans). Lexaria met en œuvre sa stratégie par le biais de collaborations, comme en témoigne un accord de transfert de matériel avec PharmaCO annoncé en septembre 2024.
Le secteur des médicaments GLP-1 devrait générer plus de 100 milliards de dollars de revenus annuels, avec des applications qui s'étendent à plusieurs domaines de la santé, notamment les maladies cardiovasculaires, la maladie rénale chronique, l'obésité et le diabète.
Lexaria Bioscience (NASDAQ:LEXX) gibt ein strategisches Update zu Entwicklungen in der GLP-1-Branche und hebt das Potenzial seiner DehydraTECH-Technologie zur Verbesserung der oralen Arzneimittelabgabe hervor. Aktuelle Branchenmeldungen umfassen die Einstellung der Entwicklung von Danuglipron durch Pfizer aufgrund von Leberverletzungsbedenken, während Eli Lilly positive Phase-3-Ergebnisse für Orfoglipron meldete, was zu einer Marktbewertungssteigerung von 100 Milliarden US-Dollar führte.
Das Unternehmen betont, dass DehydraTECH eine verbesserte Abgabeleistung bei bestehenden oralen GLP-1-Medikamenten gezeigt hat und das Potenzial besitzt, häufige Nebenwirkungen zu reduzieren, die zu hohen Abbruchraten führen (47-64 % innerhalb von 1-2 Jahren). Lexaria setzt seine Strategie durch Kooperationen um, wie ein Materialtransferabkommen mit PharmaCO zeigt, das im September 2024 bekannt gegeben wurde.
Der GLP-1-Medikamentensektor wird voraussichtlich über 100 Milliarden US-Dollar Jahresumsatz generieren, mit Anwendungen in verschiedenen Gesundheitsbereichen wie Herz-Kreislauf-Erkrankungen, chronischer Nierenerkrankung, Fettleibigkeit und Diabetes.
- DehydraTECH technology demonstrated enhanced delivery performance with existing oral GLP-1 drugs
- Active collaboration with PharmaCO through material transfer agreement
- Technology shows potential to reduce common side effects that lead to high discontinuation rates
- Positioned to benefit from rapidly growing GLP-1 market projected to exceed $100B annually
- No FDA approvals or major pharmaceutical partnerships announced yet
- Operating in highly competitive market with major pharmaceutical companies
Insights
Lexaria positions its technology to address oral GLP-1 drug limitations amid major industry developments, though commercial validation remains in early stages.
Lexaria's strategic update focuses on positioning its DehydraTECH technology as a potential solution to two critical challenges in the high-growth GLP-1 market: improving oral drug performance and reducing side effects. The timing aligns with contrasting industry developments - Pfizer abandoning danuglipron development after liver injury concerns, while Eli Lilly's orfoglipron showed promising Phase 3 results that sparked a
The GLP-1 industry faces substantial hurdles with oral dosing. Pfizer discontinued multiple oral GLP-1 candidates due to safety concerns, highlighting delivery challenges even for pharmaceutical giants. Meanwhile, Eli Lilly's successful Phase 3 candidate still showed significant side effects, with
These side effects represent a genuine commercial obstacle - studies indicate
Lexaria reports having conducted human testing with Novo Nordisk's semaglutide and demonstrated "enhanced delivery performance." The company also references reduced side effects in testing with both semaglutide and Eli Lilly's tirzepatide, though specific data metrics aren't provided.
Commercial validation remains preliminary, with Lexaria disclosing a material transfer agreement with an unnamed pharmaceutical company initiated in September 2024. This represents a standard early evaluation stage but indicates some industry interest in the technology.
The expanding applications for GLP-1 drugs beyond diabetes and weight loss - including recent FDA approval for Ozempic in chronic kidney disease - support industry projections of over
Pfizer and Eli Lilly reporting significant - and opposing - news in the GLP-1 industry
Lexaria's technology could enhance performance and lower side effects
KELOWNA, BC / ACCESS Newswire / April 23, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following glucagon-like peptide-1 ("GLP-1") strategic update following important industry developments reported both by Pfizer® Inc. and by Eli Lilly and Company®.
Nearly all of the world's top pharmaceutical companies are racing to develop new oral GLP-1 drugs, including: Amgen®, AstraZenca, Eli Lilly, Merck®, Novo Nordisk®, Pfizer®, and Roche®.
By enhancing the performance of oral dosing choices as a replacement for disliked injections; and by reducing adverse events - often the #1 reason that patients stop using GLP-1 drugs - Lexaria's proprietary DehydraTECH technology could be of vital importance to any of these companies in their pursuit of the next oral GLP-1 drug(s).
As previously announced, Lexaria has already demonstrated in human testing, enhanced delivery performance to the world's ONLY existing orally dosed GLP-1 drug: Rybelsus® (semaglutide), owned by Novo Nordisk®.
On April 14, 2025, Pfizer® announced that it would scrap development of danuglipron as a once-daily oral GLP-1 treatment after a patient in a trial experienced a liver injury possibly related to the drug. This was doubly disappointing since, in December 2023, Pfizer® had discontinued a twice-daily trial dose of danuglipron after unwanted side effects derailed an earlier study.
Similarly, Pfizer® experienced earlier setbacks in 2023 with a different GLP-1 drug, lotiglipron, when it too resulted in elevated liver enzymes in patients who took the drug in earlier clinical studies. Development of safe and effective orally-dosed GLP-1 drugs is extremely challenging even for the largest pharmaceutical companies in the world, and Pfizer® and others still need to rise to the challenge of developing effective oral GLP-1 drugs with minimal side effects.
On April 17, 2025, Eli Lilly reported that their experimental, orally-dosed GLP-1 drug (orfoglipron) resulted in lower blood sugar and lower body weight after 40 weeks in a phase 3 clinical trial. As a result of this news, Eli Lilly's market valuation increased by nearly
Eli Lilly plans to apply for approval to launch the drug for both weight loss and diabetes treatment in 2026 - and that rapid path to market, combined with the fact that it might be only the 2nd oral GLP-1 drug to potentially be approved by the Food and Drug Administration ("FDA"), is likely responsible for the dramatic market response to the news.
Although clearly a positive step forward for the weight loss and diabetes treatment sectors, it should still be noted that
Side Effects a Known Challenge.
In the studies just reported (above), and in earlier studies, unwanted side effects remain one of the largest challenges still faced by the industry, seemingly without a solution in sight. The results of another study showed that between
Obviously, side effects serious enough to persuade patients to discontinue use of an otherwise effective drug, are a major problem for the industry. For companies like Pfizer®, those side effects have been serious enough to stop drug development in its tracks.
As Lexaria reported on August 28, 2024 and January 14, 2025, DehydraTECH-GLP-1 processing has repeatedly shown its propensity to reduce side effects, including but not limited to gastrointestinal adverse events, in both of the major GLP-1 drugs currently available in the world today, being Eli Lilly's tirzepatide, and Novo Nordisk's® semaglutide. One of the only other GLP-1 drugs on the market today, liraglutide, is currently in pilot testing by Lexaria in humans utilizing DehydraTECH processing.
Lexaria is rapidly executing its multi-faceted strategy centered around its proprietary DehydraTECH processing technology. Our main goal is to attract pharmaceutical companies seeking the benefits of adopting Lexaria's technology for use with their own existing drug products. This first prong of our strategy has been evidenced and validated by the Company's entry in a material transfer agreement with a pharmaceutical company ("PharmaCO") which was announced in September of 2024. Lexaria continues to collaborate with PharmaCO on evaluating DehydraTECH compositions.
As we noted on November 26, 2024, GLP-1 drugs are either approved for use, or are being investigated for use, in all of the following healthcare sectors:
Most recently, the FDA approved Ozempic® (semaglutide) owned by Novo Nordisk®, to "reduce the risk of kidney disease worsening, kidney failure (end-stage kidney disease), and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease ("CKD"). This has the potential to literally be a life-saver for some of the 37 million adults in America struggling with CKD, which, until now, often had NO CURE.
As we noted on November 7, 2024, growth expectations for the GLP-1 industry - prior to the FDA's approval of semaglutide for treatment of CKD - supported a growing consensus that revenue in the GLP-1 drug sector will soon be over
About Lexaria Bioscience Corp. & DehydraTECH
DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 48 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
INVESTOR CONTACT:
George Jurcic - Head of Investor Relations
ir@lexariabioscience.com
Phone: 250-765-6424, ext 202
SOURCE: Lexaria Bioscience Corp.
View the original press release on ACCESS Newswire
FAQ
What results did Eli Lilly report for their oral GLP-1 drug orfoglipron in April 2025?
Why did Pfizer discontinue development of danuglipron as a GLP-1 treatment?
What are the side effects reported in Eli Lilly's oral GLP-1 drug trial?
How has LEXX's DehydraTECH technology performed in GLP-1 drug testing?
What is the current market potential for GLP-1 drugs according to LEXX?
